Mohan Pankaj Form 4 December 20, 2017

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number:

3235-0287

0.5

January 31, Expires: 2005

OMB APPROVAL

Estimated average burden hours per response...

Check this box if no longer subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Last)

(Print or Type Responses)

| 1. Name and Address of Reporting Person |
|---|
| Mohan Pankaj |
| |

(First)

(Street)

(Middle)

2. Issuer Name and Ticker or Trading Symbol

Oncobiologics, Inc. [ONS]

3. Date of Earliest Transaction (Month/Day/Year) 12/18/2017

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

C/O ONCOBIOLOGICS, INC., 7 **CLARKE DRIVE**

4. If Amendment, Date Original Filed(Month/Day/Year)

_X__ 10% Owner _X__ Director X_ Officer (give title __ Other (specify below) President & CEO

6. Individual or Joint/Group Filing(Check Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting Person

CRANBURY, NJ 08512

| (City) | (State) | (Zip) Table | e I - Non-D | erivative S | Securi | ties Acq | uired, Disposed o | f, or Beneficial | ly Owned |
|--------------------------------------|---|---|---|---------------|-----------|---|--|---|----------------|
| 1.Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) | | | Securities Fo Beneficially (D Owned Inc | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | Code V | Amount | or (D) | Price | (Instr. 3 and 4) | | |
| Common Stock | 12/18/2017 | | S | 20,523 (1) | D | \$ 1.17 (2) | 7,254,838 (3) | D | |
| Common Stock | 12/19/2017 | | S | 83,608 (1) | D | \$ 1.14 (4) | 7,171,230 (3) | D | |
| Common Stock | | | | | | | 492,753 | I | By spouse |
| Common Stock | | | | | | | 39,405 | I | By minor child |
| | | | | | | | 86,956 | I | By Trust |

Common Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of **SEC 1474** information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 4. Transact Code (Instr. 8) | 5. ionNumber of Derivativ Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | . | ate | 7. Title Amount Underly Securiti (Instr. 3 | t of ring es | 8. Price of Derivative Security (Instr. 5) | 9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr |
|---|---|--------------------------------------|--------------------------------------|---|---------------------|--------------------|--|--------------------|---|---|
| | | | Code V | (A) (D) | Date Exercisable | Expiration Date | Title N | Number | | |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | | | | |
|---|---------------|-----------|-----------------|-------|--|--|--|
| 1 | Director | 10% Owner | Officer | Other | | | |
| Mohan Pankaj C/O ONCOBIOLOGICS, INC. 7 CLARKE DRIVE CRANBURY, NJ 08512 | X | X | President & CEO | | | | |

Signatures

/s/ Lawrence Kenyon, 12/20/2017 Attorney-in-Fact

**Signature of Reporting Person Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units ("RSUs"). This sale is mandated by the Issuer's election under its equity incentive plans to (1) require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

Reporting Owners 2

Edgar Filing: Mohan Pankaj - Form 4

- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$1.12 \$1.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.
- (3) Includes 202,898 shares of the Issuer's common stock subject to RSUs that will vest on 12/31/2017, subject to continued service through such date.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$1.11 \$1.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.